Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-8455Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tsaur, Igor | - |
| dc.contributor.author | Heidegger, Isabel | - |
| dc.contributor.author | Bektic, Jasmin | - |
| dc.contributor.author | Kafka, Mona | - |
| dc.contributor.author | van den Bergh, Roderick C. N. | - |
| dc.contributor.author | Hunting, Jarmo C. B. | - |
| dc.contributor.author | Thomas, Anita | - |
| dc.contributor.author | Brandt, Maximilian P. | - |
| dc.contributor.author | Höfner, Thomas | - |
| dc.contributor.author | Debedde, Eliott | - |
| dc.contributor.author | Thibault, Constance | - |
| dc.contributor.author | Ermacora, Paola | - |
| dc.contributor.author | Zattoni, Fabio | - |
| dc.contributor.author | Foti, Silvia | - |
| dc.contributor.author | Kretschmer, Alexander | - |
| dc.contributor.author | Ploussard, Guillaume | - |
| dc.contributor.author | Rodler, Severin | - |
| dc.contributor.author | Amsberg, Gunhild von | - |
| dc.contributor.author | Tilki, Derya | - |
| dc.contributor.author | Surcel, Christian | - |
| dc.contributor.author | Rosenzweig, Barak | - |
| dc.contributor.author | Gadot, Moran | - |
| dc.contributor.author | Gandaglia, Giorgio | - |
| dc.contributor.author | Dotzauer, Robert | - |
| dc.contributor.other | EAU-YAU Prostate Cancer Working Party | - |
| dc.date.accessioned | 2022-12-01T09:38:22Z | - |
| dc.date.available | 2022-12-01T09:38:22Z | - |
| dc.date.issued | 2021 | - |
| dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/8471 | - |
| dc.description.abstract | Background Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone-sensitive prostate cancer (mHSPC). Real-world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC. Methods In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression-free survival 1 (PFS1), and progression-free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan–Meier method and log-rank test. The Cox-proportional hazards model was used for univariate and multivariate regression analyses. Results Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log-rank testing (23 vs. 13 mos., p < 0.001), a longer PFS2 (48 vs. 33 mos., p = 0.006), and longer OS (80 vs. 61 mos., p = 0.040). In the multivariate analyses AA+ADT outperformed D+ADT in terms of PFS1 (HR = 0.34, 95% CI = 0.183–0.623; p = 0.001) and PFS2 (HR = 0.33 95% CI = 0.128–0.827; p = 0.018), respectively, while OS and toxicity rate were similar between both groups. Conclusions AA+ADT is mainly associated with a similar efficacy and overall toxicity rate as D+ADT. Further prospective research is required for validation of the clinical value of the observed benefit of AA+ADT for progression-free end-points. | en_GB |
| dc.language.iso | eng | de |
| dc.rights | CC BY | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject.ddc | 610 Medizin | de_DE |
| dc.subject.ddc | 610 Medical sciences | en_GB |
| dc.title | A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer | en_GB |
| dc.type | Zeitschriftenaufsatz | de |
| dc.identifier.doi | http://doi.org/10.25358/openscience-8455 | - |
| jgu.type.dinitype | article | en_GB |
| jgu.type.version | Published version | de |
| jgu.type.resource | Text | de |
| jgu.organisation.department | FB 04 Medizin | de |
| jgu.organisation.number | 2700 | - |
| jgu.organisation.name | Johannes Gutenberg-Universität Mainz | - |
| jgu.rights.accessrights | openAccess | - |
| jgu.journal.title | Cancer medicine | de |
| jgu.journal.volume | 10 | de |
| jgu.journal.issue | 18 | de |
| jgu.pages.start | 6354 | de |
| jgu.pages.end | 6364 | de |
| jgu.publisher.year | 2021 | - |
| jgu.publisher.name | Wiley | de |
| jgu.publisher.place | Hoboken, NJ | de |
| jgu.publisher.issn | 2045-7634 | de |
| jgu.organisation.place | Mainz | - |
| jgu.subject.ddccode | 610 | de |
| jgu.publisher.doi | 10.1002/cam4.4184 | de |
| jgu.organisation.ror | https://ror.org/023b0x485 | - |
| Appears in collections: | JGU-Publikationen | |
Files in This Item:
| File | Description | Size | Format | ||
|---|---|---|---|---|---|
 | a_realworld_comparison_of_doc-20221201102756455.pdf | 467.42 kB | Adobe PDF | View/Open |